208 related articles for article (PubMed ID: 26029365)
1. Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.
Stasiolek M; Linker RA; Hayardeny L; Bar Ilan O; Gold R
Immun Inflamm Dis; 2015 Jun; 3(2):45-55. PubMed ID: 26029365
[TBL] [Abstract][Full Text] [Related]
2. Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
Lund BT; Kelland EE; Hayardeny L; Barilan O; Gilmore W; Weiner LP
J Neuroimmunol; 2013 Oct; 263(1-2):108-15. PubMed ID: 23920036
[TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Filippi M; Rocca MA; Pagani E; De Stefano N; Jeffery D; Kappos L; Montalban X; Boyko AN; Comi G;
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):851-8. PubMed ID: 24029546
[TBL] [Abstract][Full Text] [Related]
4. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
Ziemssen T; Tumani H; Sehr T; Thomas K; Paul F; Richter N; Samara E; Spiegelstein O; Sorani E; Bar-Ilan O; Mimrod D; Hayardeny L
J Neuroinflammation; 2017 Aug; 14(1):172. PubMed ID: 28859672
[TBL] [Abstract][Full Text] [Related]
5. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Jolivel V; Luessi F; Masri J; Kraus SH; Hubo M; Poisa-Beiro L; Klebow S; Paterka M; Yogev N; Tumani H; Furlan R; Siffrin V; Jonuleit H; Zipp F; Waisman A
Brain; 2013 Apr; 136(Pt 4):1048-66. PubMed ID: 23518712
[TBL] [Abstract][Full Text] [Related]
6. The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Zilkha-Falb R; Gurevich M; Hayardeny L; Achiron A
J Neuroimmunol; 2015 Jun; 283():11-6. PubMed ID: 26004150
[TBL] [Abstract][Full Text] [Related]
7. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Thöne J; Ellrichmann G; Seubert S; Peruga I; Lee DH; Conrad R; Hayardeny L; Comi G; Wiese S; Linker RA; Gold R
Am J Pathol; 2012 Jan; 180(1):267-74. PubMed ID: 22152994
[TBL] [Abstract][Full Text] [Related]
8. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Comi G; Pulizzi A; Rovaris M; Abramsky O; Arbizu T; Boiko A; Gold R; Havrdova E; Komoly S; Selmaj K; Sharrack B; Filippi M;
Lancet; 2008 Jun; 371(9630):2085-92. PubMed ID: 18572078
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Comi G; Jeffery D; Kappos L; Montalban X; Boyko A; Rocca MA; Filippi M;
N Engl J Med; 2012 Mar; 366(11):1000-9. PubMed ID: 22417253
[TBL] [Abstract][Full Text] [Related]
10. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.
Varrin-Doyer M; Zamvil SS; Schulze-Topphoff U
Exp Neurol; 2014 Dec; 262 Pt A():66-71. PubMed ID: 24731945
[TBL] [Abstract][Full Text] [Related]
11. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Hainke U; Thomas K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):701-9. PubMed ID: 27089834
[TBL] [Abstract][Full Text] [Related]
12. Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.
Dobson L; Träger U; Farmer R; Hayardeny L; Loupe P; Hayden MR; Tabrizi SJ
J Neurochem; 2016 Jun; 137(5):782-94. PubMed ID: 26823290
[TBL] [Abstract][Full Text] [Related]
13. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis.
Thöne J; Gold R
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):365-70. PubMed ID: 21306281
[TBL] [Abstract][Full Text] [Related]
14. Oral laquinimod treatment in multiple sclerosis.
Fernández O
Neurologia; 2011 Mar; 26(2):111-7. PubMed ID: 21163185
[TBL] [Abstract][Full Text] [Related]
15. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
[TBL] [Abstract][Full Text] [Related]
16. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Comi G; Abramsky O; Arbizu T; Boyko A; Gold R; Havrdová E; Komoly S; Selmaj K; Sharrack B; Filippi M;
Mult Scler; 2010 Nov; 16(11):1360-6. PubMed ID: 20834039
[TBL] [Abstract][Full Text] [Related]
17. Insight into the mechanism of laquinimod action.
Brück W; Wegner C
J Neurol Sci; 2011 Jul; 306(1-2):173-9. PubMed ID: 21429524
[TBL] [Abstract][Full Text] [Related]
18. Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.
Sørensen PS; Comi G; Vollmer TL; Montalban X; Kappos L; Dadon Y; Gorfine T; Margalit M; Sasson N; Rubinchick S; Knappertz V
Int J MS Care; 2017; 19(1):16-24. PubMed ID: 28243182
[TBL] [Abstract][Full Text] [Related]
19. Oral laquinimod therapy in relapsing multiple sclerosis.
Preiningerova J
Expert Opin Investig Drugs; 2009 Jul; 18(7):985-9. PubMed ID: 19527103
[TBL] [Abstract][Full Text] [Related]
20. Defining a role for laquinimod in multiple sclerosis.
Kieseier BC
Ther Adv Neurol Disord; 2014 Jul; 7(4):195-205. PubMed ID: 25002907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
